about
Biomarkers indicative of blood-brain barrier disruption in multiple sclerosisDefining the clinical course of multiple sclerosis: the 2013 revisions.Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteriaThe challenge of comorbidity in clinical trials for multiple sclerosisRecommendations for observational studies of comorbidity in multiple sclerosis.Update on biomarkers in neuromyelitis opticaHumoral-targeted immunotherapies in multiple sclerosisUse of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum DisorderB-cell depletion with rituximab in relapsing-remitting multiple sclerosisA serial study of new MS lesions and the white matter from which they ariseVanishing MS T2-bright lesions before puberty: a distinct MRI phenotype?Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic reviewGenome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosisThe gut microbiome in human neurological disease: A review.Relapses in multiple sclerosis: Relationship to disability.International Pediatric MS Study Group Global Members Symposium report.Younger children with MS have a distinct CSF inflammatory profile at disease onsetMS and the B cell controversy.Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndromeSwitching multiple sclerosis patients with breakthrough disease to second-line therapy.NMDA receptor encephalitis mimicking seronegative neuromyelitis opticaA randomized controlled phase II trial of riluzole in early multiple sclerosis.Longitudinal evaluation of cognitive functioning in pediatric multiple sclerosis: report from the US Pediatric Multiple Sclerosis Network.Precision medicine in chronic disease management: The multiple sclerosis BioScreen.Protective environmental factors for neuromyelitis opticaVitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis.Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.Multiple sclerosis susceptibility genes: associations with relapse severity and recovery.Association of multiple sclerosis susceptibility variants and early attack location in the CNSCommon viruses associated with lower pediatric multiple sclerosis risk.Quantitative MRI analysis in children with multiple sclerosis: a multicenter feasibility pilot study.Vitamin D status and antibody levels to common viruses in pediatric-onset multiple sclerosis.Treatment adherence and transitioning youth in pediatric multiple sclerosisThe US Network of Pediatric Multiple Sclerosis Centers: Development, Progress, and Next Steps.Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies.Patient preferences for attributes of multiple sclerosis disease-modifying therapies: development and results of a ratings-based conjoint analysis.Emerging disease modifying therapies for multiple sclerosis.Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS studyGut microbiota composition and relapse risk in pediatric MS: A pilot study.Associations between the gut microbiota and host immune markers in pediatric multiple sclerosis and controls
P50
Q21343009-8154C7FB-6437-42E1-A8D0-A981267C6F92Q22241654-A57DAB56-D303-4371-A1C5-0CE2D2748505Q24605493-13000033-DA18-4D89-B9C0-E2A83B7B8D31Q26765031-0CD6A226-3960-434C-BDCA-48EF9E2FCA5CQ26766688-39F3B94D-4DF5-43B5-98BB-6285A9862C48Q26799789-622EED74-B0B6-4A08-A2FB-E161AB11D3E1Q26865971-A96A1B9E-6899-4556-81EB-B3262D8426BDQ28085378-F7C679FA-B6FF-46EC-8B72-C7E3FE85D5F5Q28268626-93E85F93-C82A-4492-8239-052326E0C540Q28291585-830EE77D-9261-4240-AA64-83C2B32A8E30Q28295514-E410864A-1708-4CB3-9F71-1C94FC1013A4Q28534465-4E159628-B7D1-4026-8A07-54D11E84BE79Q28943261-95D23153-94FF-4EAC-A445-F6A43CC25A08Q30490923-A044DE46-13EE-4B71-8D15-D954AF96F39BQ31072834-DA15EC3C-DB58-452F-B286-B8DDA184F983Q31125318-0B898FD7-1D38-4C68-85A9-7483BDCE19BFQ33628846-B193FC4E-0635-41DF-9F2C-C530E881D0ADQ33646322-70124380-E316-43A8-914B-4D7B3E9D6736Q33804832-60CE0C17-01E8-4EF7-AE54-FA5C19772C71Q33815455-F3C8ED0E-7A0B-4906-A98A-84FDF8450CE5Q33861349-9B7BC8D6-C81B-4D17-A3E4-2814F43D6842Q34286809-87185E4B-0BE7-40FF-9357-CA0F7414F2E6Q34315953-8CC23D66-998F-4AF7-8325-BBD262DEF3B1Q34429211-684FCC4C-D0A9-4772-9C9C-32CBF805A51FQ34591273-AB099926-DB10-4E5A-8D83-D450CB7D0C08Q34641782-3317234E-CAF1-4FDE-80AB-8187A07A2530Q34856849-466F8259-002D-491C-B280-C747333AA726Q35018274-26D84784-DD4D-4122-97DA-50F4553FC043Q35018315-AA9DCCE0-795D-4D4D-A9B6-D630B64C0F59Q35030410-FDC57466-9692-4783-93BC-B83309060D1EQ35041978-C7F79189-0AAF-4CC4-B68A-AD8BE55B3F06Q35098876-5A74A544-6F1A-4C3F-99CB-A68C4F0215D5Q35182797-5DF88EAC-E6D8-4B4B-845F-3EA615C231CCQ35231717-D3DC948F-7A59-4429-AC53-D0796934B5B4Q35377133-8BC08EAD-4BCF-49AE-AE9B-06080B32FE20Q35446549-FF24095C-BE14-41DA-81F4-BD9CEBEB7EEEQ35581158-568C1281-7725-4012-BA50-66AA3EEB5335Q35872344-CAC924B2-A9C1-4530-B61B-4EAFAC20D15FQ35965204-DBC0E630-B645-4CF8-86B1-E5CACC8ABF48Q36139341-181C2EC6-4B93-4F37-AF48-1826BEAB250E
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Emmanuelle Waubant
@ast
Emmanuelle Waubant
@en
Emmanuelle Waubant
@es
Emmanuelle Waubant
@nl
Emmanuelle Waubant
@sl
type
label
Emmanuelle Waubant
@ast
Emmanuelle Waubant
@en
Emmanuelle Waubant
@es
Emmanuelle Waubant
@nl
Emmanuelle Waubant
@sl
prefLabel
Emmanuelle Waubant
@ast
Emmanuelle Waubant
@en
Emmanuelle Waubant
@es
Emmanuelle Waubant
@nl
Emmanuelle Waubant
@sl
P214
P244
P106
P21
P213
0000 0003 8408 0513
P214
P244
n2010184066
P31
P735
P7859
lccn-n2010184066